Micron To Rally Around 187%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P
Stocks · News reference
Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoint; Buy on Ambiq Micro; Overweight on Abbott.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P
Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.
Jefferies analyst Kevin Garrigan initiates coverage on Ambiq Micro (NYSE:AMBQ) with a Buy rating and announces Price Target of $90.
Stifel analyst Tore Svanberg maintains Ambiq Micro (NYSE:AMBQ) with a Buy and raises the price target from $75 to $85.